Pfizer has launched its new Rimegepant orally disintegrating tablet (ODT) in India for the acute treatment of migraine, with or without aura, in adults who have previously shown insufficient response to triptans. Approved by the Drug Controller General of India (DCGI), the 75 mg ODT can be taken with or without food and dissolves without the need for water, offering convenience and rapid action.
Pfizer said the medication provides quick and sustained pain relief for up to 48 hours and does not carry the risk of medication overuse headaches. By targeting the calcitonin gene-related peptide (CGRP), a key factor in migraine pathophysiology, Rimegepant aims to set a new benchmark in migraine management in the country.
In Kolkata, neurologists and pharmacists expect strong interest as the city reports a rising number of migraine cases among working professionals. With patients increasingly seeking fast-acting and easy-to-use solutions, the new ODT format is likely to see quick adoption across major hospitals and retail pharmacies. “We are excited to bring Rimegepant to India,” said MeenakshiNevatia, Managing Director, Pfizer India. “This treatment will help people with migraine manage pain more effectively and reclaim productive days sooner.” With India reporting nearly 213 million migraine sufferers annually and an estimated 17.3 days of productivity lost per patient per year, Pfizer aims to address a critical healthcare gap with this new therapy.